Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2012	Aug. 09, 2012
Document And Entity Information
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	0000025743
Document Type	10-Q
Document Period End Date	Jun. 30, 2012
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	95,750,212	95,800,807
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2012

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Consolidated Balance Sheets
Cash	$ 1,327,013	$ 126,421
Accounts receivable, net of allowance for doubtful accounts of $16,523 and $1,500, respectively	407,929	26,720
Inventory	820,241	588,073
Other current assets	899,810	496,060
Total current assets	3,454,993	1,237,274
Property and equipment, net	107,405	70,113
Other Assets:
Prepaid Expenses	1,215,340	80,515
Patent costs	68,054	18,870
Security deposit	31,949	31,949
[AssetsNoncurrent]	1,315,343	131,334
Total assets	4,877,741	1,438,721
Accounts payable	692,132	306,511
Deferred Revenue	618,877
Notes payable	299,220	2,150,000
Notes payable, related parties	150,000	200,000
Accrued interest	13,518	28,321
Other current liabilities	714,196	465,747
Total current liabilities	2,487,943	3,150,579
Long-Term Liabilities:
Notes payable, net of debt discount of $1,597,644 and $0, respectively	3,094,203
Total liabilities	5,582,146	3,150,579
Commitments and Contingencies
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 250,000,000 shares authorized; 95,750,212 and 82,978,804 issued and outstanding, respectively	95,750	82,979
Additional paid in capital	41,332,564	15,198,241
Accumulated deficit	(42,132,719)	(16,993,078)
Total stockholder' deficit	(704,405)	(1,711,858)
Total liabilities and stockholders' deficit	$ 4,877,741	$ 1,438,721

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Consolidated Balance Sheets Parenthetical
Allowance for doubtful accounts	$ 16,523	$ 1,500
Debt discount on notes payable	$ 1,597,644	$ 0
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	95,750,212	82,978,804
Common stock, shares outstanding	95,750,212

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Condensed Consolidated Statements Of Operations
Revenues, net	$ 819,150	$ 508,303	$ 1,540,842	$ 994,159
Cost of goods sold	372,370	238,976	708,494	442,732
Gross profit	446,780	269,327	832,348	551,427
Operating expenses:
Sales, general, and administration	3,573,485	1,200,411	6,400,535	2,185,530
Research and development	833,342	106,019	1,245,303	160,730
Depreciation and amortization	14,535	13,711	29,113	27,422
Total operating expense	4,421,362	1,320,141	7,674,951	2,373,682
Operating loss	(3,974,582)	(1,050,814)	(6,842,603)	(1,822,255)
Other income and (expense)
Miscellaneous Income	1,554		1,554
Loss on extinguishment of debt			(10,307,864)
Beneficial Conversion Feature	(6,716,504)		(6,716,504)
Amortization of debt discount	(1,055,984)	(3,590)	(1,109,276)	(3,590)
Interest expense	(92,777)	(232)	(141,458)	(232)
Loan guaranty costs	(11,745)	(11,745)	(23,490)	(14,669)
Total other income (expense)	(7,875,456)	(15,567)	(18,297,038)	(18,491)
Loss before taxes	(11,850,038)	(1,066,381)	(25,139,641)	(1,840,746)
Provision for income taxes
Net loss	$ (11,850,038)	$ (1,066,381)	$ (25,139,641)	$ (1,840,746)
Loss per share, basic and diluted:
Net loss per share, basic and diluted	$ (0.14)	$ (0.02)	$ (0.29)	$ (0.03)
Weighted average number of shares outstanding	86,149,419	57,455,491	85,352,818	56,700,657

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
CASH FLOWS FROM OPERATING ACTIVITIES - CONTINUING OPERATIONS
Net loss	$ (25,139,641)	$ (1,840,746)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	29,113	27,422
Provision for doubtful accounts	15,023
Loss on debt extinguishment	10,307,864
Beneficial Conversion Feature	(6,716,504)
Amortization of debt discount	1,109,276	3,590
Stock based compensation	529,129	98,236
Stock based expense for services	120,120
Loan guaranty costs	23,490	14,669
Changes in assets and liabilities
Accounts receivable	(396,232)	(20,969)
Inventory	(232,168)	(574)
Other current assets	282,090	(4,557)
Deferred Revenue	618,877
Accounts payable	385,620	113,624
Accrued interest	133,702
Accrued expenses and other current liabilities	258,450	46,786
Net cash flows used in operating activities	(5,248,783)	(1,562,519)
CASH FLOWS FROM INVESTING ACTIVITIES
Vendor deposits	(400,656)	(260,667)
Purchase of property and equipment	(66,404)	(25,953)
Patent costs, net of abandoned costs	(49,184)
Net cash flows used in investing activities	(516,244)	(286,620)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from notes and loans payable	6,900,000	650,149
Proceeds from exercise of options	165,999
Proceeds from sale of warrants	400
Proceeds from sale of membership units		707,000
Proceeds from notes payable - related parties		150,084
Repayment of notes payable	(50,780)	(2,778)
Repayment of notes payable - related party	(50,000)
Net cash flows provided by financing activities	6,965,619	1,504,455
Increase (decrease) in cash	1,200,592	(344,684)
Cash, beginning of period	126,421	422,939
Cash, end of period	1,327,013	78,255
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	7,756
Cash paid for income taxes
Warrants exercised in exchange for debt and accrued interest	3,102,000
Warrants issued for financing	2,509,537
Warrants issued for services	1,532,228
Shares issued in exchange for debt and accrued interest	1,054,658
Notes payable issued for accrued interest	$ 15,123

THE COMPANY

6 Months Ended

Jun. 30, 2012

Notes to Financial Statements

THE COMPANY

NOTE 1 – THE COMPANY

Nature of Operations

TherapeuticsMD, Inc. ("Therapeutics" or the "Company"), through its wholly owned subsidiary vitaMedMD, LLC ("VitaMed"), is a specialty pharmaceutical company focused on providing the highest quality products to the women's health market to improve women’s health and wellness. Our national sales force that calls on physicians and pharmacies is enhanced by our patent-pending technology and business methodology. This combination allows us to market both over-the-counter ("OTC") and prescription nutritional supplements, drugs, medical foods and other medical products through pharmacies and our web-site with the recommendation of physicians by creating a unique value proposition for patients, physician/providers and insurance payors.

New Products

On March 1, 2012, the Company launched its first prescription prenatal vitamin, vitaMedMD™ Plus Rx. vitaMedMD Plus Rx is a single-dose product containing one prenatal vitamin tablet and one life’s DHA capsule.

On April 9, 2012, the Company launched its second prescription prenatal vitamin, vitaMedMD™ Plus One. vitaMedMD Plus One is a single dose containing one softgel with 14 vitamins, minerals and 200 mg of plant-based DHA.

On May 10, 2012, the Company launched its third prescription prenatal vitamin, vitaMedMD™RediChew™ Rx. vitaMedMD RediChew Rx is a small, vanilla flavored, chewable prenatal vitamin tablet that dissolves quickly and is taken once daily.

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the six months ended June 30, 2012, the Company incurred a loss from operations of approximately $6,843,000 had negative cash flows from operations of approximately $5,249,000 and had an accumulated deficit of approximately $42,133,000. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans include raising additional proceeds from debt and equity transactions and to continue to increase its sales and marketing activities, however, there are no assurances that management will be successful in their efforts. The financial statements do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.

NOTES PAYABLE	6 Months Ended
NOTES PAYABLE	Jun. 30, 2012
Notes to Financial Statements
NOTES PAYABLE	NOTE 9 – NOTES PAYABLE Issuance of Promissory Notes In January and February 2012, the Company sold six-percent promissory notes (the "Promissory Notes") for an aggregate of $900,000 with due dates of March 1, 2012. As discussed below, these Promissory Notes were modified on February 24, 2012 through the issuance of secured promissory notes (the "February 2012 Notes"). Issuance of February 2012 Notes On February 24, 2012, the Company sold and issued the February 2012 Notes to an individual and an entity (the “Parties”), both of which are shareholders of the Company, in the principal base amount of $1,358,014 and $1,357,110 respectively (the "Principal Base Amount(s)") and granted Warrants for the purchase in the aggregate of 9,000,000 shares (4,500,000 to each Party) (the "February 2012 Warrants") pursuant to the terms of a Note Purchase Agreement (the "Note Purchase Agreement") also dated February 24, 2012. As consideration for the Februay 2012 Notes and the February 2012 Warrants, the Company received an aggregate of $1,000,000 of new funding from the Parties (the "New Funding") and the Parties surrendered certain promissory notes previously issued by the Company in the amount of $1,700,000 plus accrued interest of $15,124 (collectively known as the "Prior Notes"). The Company granted 5,685,300 Warrants in consideration of the modification of the Prior Notes and 3,314,700 Warrants with the New Funding. The Company determined that the resulting modification of the Prior Notes was substantial in accordance with ASC 470-50, “Modifications and Extinguishments.” As such the modification was accounted for as an extinguishment and restructuring of the debt, and the 5,685,300 warrants issued were expensed. The fair value of the Prior Notes was estimated by calculating the present value of the future cash flows discounted at a market rate of return for comparable debt instruments to be $1,517,741, resulting in a debt discount of $197,583. The Company recognized a loss on extinguishment of debt of $10,307,864 which represented the fair value of the 5,685,300 warrants net of the difference between the carrying amount of the Prior Notes and their fair value as of the date of the modification. The Company determined the relative fair value of the 3,314,700 Warrants granted with the New Funding to be $859,647 and recorded the amount as debt discount to be amortized over the term of the February 2012 Notes. As a result of the surrender of the February 2012 Notes on June 19, 2012 (see Issuance of June 2012 Notes below), the Company expensed the remaining unamortized debt discount. As of June 30, 2012, the Company recorded interest expense totaling $859,647 related to the February 2012 Notes. Under the February 2012 Notes, the Parties loaned the Company an additional $2,000,000 during March, April, and May 2012. On June 19, 2012 the Company settled $3,102,000 in principle and interest of the February 2012 Notes in exchange for the exercise of 8,145,486 Common Stock purchase warrants. As discussed below, the remaining balance of $2,691,847 of the February 2012 Notes was modified on June 19, 2012 through the issuance of secured promissory notes (the "June 2012 Notes"). Issuance of June 2012 Notes On June 19, 2012, the Company sold and issued the June 2012 Notes to the same Parties described in the paragraph above in the principal base amount of $2,347,128 and $2,344,719 respectively pursuant to the terms of a Note Purchase Agreement. As consideration for the June 2012 Notes, the Parties surrendered the remaining balance of the February 2012 Notes in the aggregate amount of $1,347,128 and $1,344,719, respectively (which sums included principle and interest through June 19, 2012), and the Company received an aggregate of $2,000,000 of new funding from the Parties (the "New Funding"). The principal base amount of each of the June 2012 Notes, plus any additional advance made to the Company thereafter, together with accrued interest at the annual rate of six percent (6%), is due in one lump sum payment on February 24, 2014. As security for the Company’s obligations under the Note Purchase Agreement and the June 2012 Notes, the Company entered into a Security Agreement and pledged all of its assets, tangible and intangible, as further described therein. The Company granted 7,000,000 Warrants in connection with the New Funding. The Company determined the relative fair value of the 7,000,000 Warrants to be $1,649,890 and recorded this amount as a debt discount to be amortized over the term of the June 2012 Notes. In conjunction with the February 2012 Notes and June 2012 Notes, for the three and six months ended June 30, 2012, the Company recorded an aggregate of $67,095 and $98,698, respectively, as amortization of debt discount on the accompanying condensed consolidated financial statements. At June 30, 2012, the Company reported a notes payable balance of $3,094,203, net of debt discount of $1,597,644, in long-term liabilities on the accompanying condensed consolidated financial statements. Conversion of July 2011 Secured Notes In July 2011, VitaMed sold two Senior Secured Promissory Notes (the "Secured Notes") to the Parties described in the paragraphs above in the amount of $500,000 each and also entered into a Security Agreement under which VitaMed pledged all of its assets to secure the obligation. The Secured Notes bear interest at the rate of six percent (6%) per annum, are due on the one (1) year anniversary thereof, and are convertible into shares of the Company's Common Stock at the option of the Company. The Company may pay the Secured Notes by delivering such number of shares of the Company's Common Stock as shall be determined by dividing the outstanding principal then due and owing by the Company's Share Price. For purposes of the Secured Notes, the "Share Price" shall mean the lower of the most recent price at which the Company offered and sold shares of its Common Stock (not including any shares issued upon the exercise of options and/or warrants or upon the conversion of any convertible securities) or the five-day average closing bid price immediately preceding the date of conversion. On June 19, 2012, the Company and the Parties agreed to convert the Secured Notes, and according to the terms thereof, aggregated principal and interest through June 19, 2012 of $1,054,647 was converted at $0.38 per share into an aggregate of 2,775,415 shares of the Company's Common Stock. This resulted in a beneficial conversion feature of $6,716,504 as recorded in other income and expense on the accompanying condensed consolidated financial statements. For the three and six months ended June 30, 2012, the Company recorded an aggregate of $18,246 and $33,204, respectively, as interest expense on the accompanying condensed consolidated financial statements. March 2011 Bank Line of Credit In March 2011, VitaMed entered into a Business Loan Agreement and Promissory Note with First United Bank for a $300,000 bank line of credit (the "Bank LOC") for which a personal guarantee and cash collateral was required. Personal guarantees and cash collateral limited to $100,000 each were provided by Robert Finizio and John Milligan, officers of VitaMed, and by Reich Family Limited Partnership, an entity controlled by Mitchell Krassan, also an officer of VitaMed. In consideration for the personal guarantees and cash collateral, Warrants for an aggregate of 613,713 shares were granted. The Bank LOC accrued interest at the rate of 3.020% per annum based on a year of 360 days and was due on March 1, 2012. The bank and VitaMed negotiated a one-year extension to the Bank LOC which was executed on March 19, 2012 (the "Bank LOC Extension"). The Bank LOC Extension accrues interest at the rate of 2.35% and is due on March 1, 2013. At June 30, 2012, the outstanding principle balance of the Bank LOC was $299,220. During the three and six months ended June 30, 2012, interest expense of $1,777 and $4,709, respectively was paid and is included in interest expense on the accompanying condensed consolidated financial statements. Issuance of VitaMed Promissory Notes In June 2011, VitaMed sold Promissory Notes (the "VitaMed Promissory Notes") in the aggregate of $500,000. In consideration for the VitaMed Promissory Notes, Warrants for an aggregate of 613,718 shares were granted. The VitaMed Promissory Notes earn interest at the rate of four percent (4%) per annum and were due at the earlier of (i) the six (6) month anniversary of the date of issuance and (ii) such time as VitaMed received the proceeds of a promissory note(s) issued in an amount of not less than $1,000,000 (the "Funding"). Upon the closing of the Funding in July 2011, as more fully described above in Conversion of July 2011 Secured Notes, two of the VitaMed Promissory Notes in the aggregate of $200,000 were paid in full. By mutual agreement, the remaining VitaMed Promissory Notes in the aggregate of $300,000 were extended. In October 2011, one of the VitaMed Promissory Notes for $50,000 was paid in full. By mutual agreement, VitaMed Promissory Notes in the aggregate of $100,000 were converted into 266,822 shares of the Company's Common Stock at $0.38 per share, which represents fair value of the shares on the date of conversion. The remaining VitaMed Promissory Notes in the aggregate of $150,000 were extended to June 1, 2012 (one held by Mr. Milligan for $50,000, one for $50,000 held by BF Investments, LLC (owned by Brian Bernick, a member of the board of directors of the Company) and one held by an unaffiliated individual for $50,000). In June 2012, the VitaMed Promissory Note held by the unaffiliated individual was paid in full including $2,160 in accrued interest. In December 2011, the Company sold four-percent Promissory Notes to Mr. Finizio and Mr. Milligan and for an aggregate of $100,000 ($50,000 each) with due dates of March 1, 2012 (the "Notes"). These Notes were extended by mutual agreement to June 1, 2012. In June 2012, the VitaMed Promissory Note held by Mr. Finizio was paid in full including $888 in accrued interest. For the three and six months ended June 30, 2012, the Company recorded an aggregate of $2,352 and $4,847, respectively, as interest expense on the accompanying condensed consolidated financial statements. At June 30, 2012, the Company reported a notes payable, related parties balance of $150,000.

DEPOSITS HELD BY VENDORS	6 Months Ended
DEPOSITS HELD BY VENDORS	Jun. 30, 2012
Notes to Financial Statements
DEPOSITS HELD BY VENDORS	NOTE 15 – DEPOSITS HELD BY VENDORS During the six months ended June 30, 2012 and in December 2011, the Company paid approximately $763,000 and $245,000, respectively, to a non-affiliated third party vendor and shareholder for fees related to research and development of new products. During the three and six months ended June 30, 2012, approximately $579,000 and $873,000, respectively, was charged to expense leaving an unused balance of approximately $135,000, which is recorded as deposits to vendors in the accompanying consolidated condensed financial statements. The Company believes that it will incur additional related fees in 2012 in the approximate amount of $1,100,000. During the six months ended June 30, 2012 and in December 2011, the Company paid approximately $309,000 and $55,000, respectively, to a non-affiliated third party vendor and shareholder as down payments on inventory purchases. These down payments were recorded as deposits with vendors in the accompanying consolidated condensed financial statements. During the three and six months ended June 30, 2012, approximately $127,000 and $161,000, respectively, was applied to inventory purchases leaving an unused balance of approximately $203,000. During the six months ended June 30, 2012, the Company paid approximately $63,000 to a non-affiliated third party vendor as down payments on inventory purchases. This down payment was recorded as deposits with vendors in the accompanying consolidated condensed financial statements. During the six months ended June 30, 2012, nothing was applied to inventory purchases leaving an unused balance of approximately $63,000.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Jun. 30, 2012
Notes to Financial Statements
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company ("VitaMed") and BocagreenMD, Inc., a Nevada corporation ("Bocagreen"), Bocagreen was formed by the Company on January 10, 2012 and is currently without operations. All material intercompany balances and transactions have been eliminated in consolidation.
Revenue Recognition	Revenue Recognition The Company recognizes revenue on arrangements in accordance with ASC 605, "Revenue Recognition" (“ASC 605”). Revenue is recognized only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed and collectability is reasonably assured. Over The Counter Products The Company generates OTC revenue by sales of products primarily to retail consumers. The Company’s policy is to recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. Outbound shipping and handling fees are included in sales and are billed upon shipment. Shipping expenses are included in cost of sales. The majority of the Company’s sales are paid with credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to sales. We provide an unconditional thirty-day money-back return policy whereby we accept product returns from our retail and eCommerce customers. The Company’s revenue from OTC sales is recognized net of returns, sales discounts, and eCommerce fees. For the six months ended June 30, 2012 and 2011, the Company recorded an allowance for returns of $28,156 and $10,756, respectively. The Company estimates the allowance for returns based on historical return activity, which is reviewed, and adjusted if necessary, on a quarterly basis. Prescription Products The Company’s prescription products are sold primarily through drug wholesalers and retail pharmacies. The Company’s revenue from prescription product sales is recognized net of sales discounts and end-user rebates. The Company accepts returns of unsalable product from customers within a return period of six months prior to and following product expiration. The Company’s prescription products currently have a shelf-life of 24 months from date of manufacture. Given the limited history of prescriptions products, the Company currently cannot reliably estimate expected returns of the prescription products at the time of shipment. Accordingly, the Company defers recognition of revenue on prescription products until the right of return no longer exists, which occurs at the earlier of the time the prescription products are dispensed through patient prescriptions or expiration of the right of return. As a result of this policy, the Company has a deferred revenue balance of approximately $619,000 at June 30, 2012. The Company maintains various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The rebate program is designed to enable the end-user to return a coupon to the Company. If the coupon qualifies, the Company sends a rebate check to the end-user. The Company estimates the allowance for rebates based on industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. For the six months ended June 30, 2012 and 2011, the Company recorded rebate expense of $11,740 and $0, respectively.
Inventories	Inventories Inventories represent packaged nutritional products and supplements which are valued at the lower of cost or market using the average cost method. The costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) are record as deferred costs, which are included in inventory, until such time as the related deferred revenue is recognized.
Use of Estimates	Use of Estimates The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

THE COMPANY (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
THE COMPANY (Details Narrative) (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Company Details Narrative
Operating loss	$ (3,974,582)	$ (1,050,814)	$ (6,842,603)	$ (1,822,255)
Net cash flows used in operating activities			(5,248,783)	(1,562,519)
Accumulated deficit	$ (42,132,719)		$ (42,132,719)		$ (16,993,078)

Inventory (Details) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Inventory Details
Finished Product	$ 757,244	$ 588,073
Deferred Costs	62,997	0
Inventory	$ 820,241	$ 588,073

OTHER CURRENT ASSETS (Details) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Other Current Assets Details
Deposits with Vendors (Note 15)	$ 400,656	$ 300,503
Prepaid consulting	395,810	95,962
Prepaid Insurance	69,027	52,611
Prepaid guaranty costs	32,320	46,984
Other prepaid costs	1,997	0
Other current assets	$ 899,810	$ 496,060

FIXED ASSETS (Details) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Fixed Assets Details
Website	$ 91,743	$ 91,743
Equipment	67,669	33,651
Furniture and fixtures	58,605	26,219
Total Fixed Assets, Gross	218,017	151,613
Accumulated depreciation	(110,612)	(81,500)
Property and equipment, net of accumulated depreciation of $96,078 and $81,500, respectively	$ 107,405	$ 70,113

FIXED ASSETS (Details Narrative) (USD $)	6 Months Ended
FIXED ASSETS (Details Narrative) (USD $)	Jun. 30, 2012	Jun. 30, 2011
Fixed Assets Details Narrative
Depreciation Expense	$ 29,113	$ 27,422

OTHER ASSETS (Details) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Other Assets Details
Prepaid Consulting	$ 1,215,340	$ 71,689
Prepaid GuarantyCosts	0	8,826
Total Other Current Assets	$ 1,215,340	$ 80,515

OTHER CURRENT LIABILITIES (Details) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Other Current Liabilities Details
Accrued payroll and commission	$ 416,631	$ 295,915
Accrued vacation	178,812	68,438
Other accrued expenses	77,394	60,035
Dividends payable(1)	41,359	41,359
Other current liabilities	$ 714,196	$ 465,747

OTHER CURRENT LIABILITIES (Details Narrative) (USD $)	Jun. 30, 2012
Other Current Liabilities Details Narrative
Dividends Payable, amount per share	$ 0.40

NOTES PAYABLE (Details Narrative) (USD $)	3 Months Ended		6 Months Ended
NOTES PAYABLE (Details Narrative) (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Promissory notes sold in January and February 2012	$ 900,000		$ 900,000
Promisory notes, principal	3,102,000		3,102,000
Loss on extinguishment of debt			(10,307,864)
Warrants exercised in exchange for debt and accrued interest			3,102,000
Warrants exercised in exchange for debt and accrued interest, number warrants			8,145,486
Amortization of debt discount	1,055,984	3,590	1,109,276	3,590
Notes payable, net of debt discount of $1,597,644 and $0, respectively	3,094,203		3,094,203
Debt discount on notes payable	1,597,644		1,597,644		0
Beneficial Conversion Feature	(6,716,504)		(6,716,504)
First United line of credit, maximum	300,000		300,000
First United line of credit, Personal Guarantees	100,000		100,000
First United line of credit, Personal Guarantees Warrants Issued			613,713
First United line of credit, Interest Rate	3.02%		3.02%
First United line of credit, extension Interest Rate			2.35%
First United line of credit, Outstanding Principal	299,220		299,220
Notes Term			6
Notes Paydown July 2011			200,000
Notes extension			300,000
Notes Paydown October 2011			50,000
VitaMed Promissory Notes Extended October 2011			150,000
VitaMed Promissory Notes Extended October 2011 - Milligan			50,000
VitaMed Promissory Notes Extended October 2011 - BF Investments			50,000
VitaMed Promissory Notes Extended October 2011 - Unaffiliated Individual			50,000
Interest Accrued - VitaMed Promissory Notes			2,160
Promissory Notes Issued December 2011			100,000
Promissory Notes Issued December 2011, value of each note			50,000
Promissory Notes Issued December 2011 outstanding balance	100,000		100,000
Interest Accrued - Promissory Notes Issued December 2011			888
Notes payable, related parties	150,000		150,000		200,000
February 24 Debt Issuance
New Funding			1,000,000
Notes surrendered			1,700,000
Accrued Interest forfeited			15,124
Warrants Issued - Note Modification			5,685,300
Warrants Issued - new Funding			3,314,700
Fair Value of Prior Notes Extinguished			1,517,741
Debt Discount from February 24, 2012 note			197,583
Loss on extinguishment of debt			10,307,864
FV Warrants - treated as Debt Discount			859,647
Interest Expense			859,647
Additional Funding - March-May2012			2,000,000
Warrants exercised in exchange for debt and accrued interest			3,102,000
Warrants exercised in exchange for debt and accrued interest, number warrants			8,145,486
June 19 Debt Issuance
New Funding			2,000,000
Notes surrendered			2,691,847
Warrants Issued - new Funding			7,000,000
FV Warrants - treated as Debt Discount			1,649,890
Interest Rate of June 19, 2012 notes			6.00%
Amortization of debt discount	52,246		52,246
Debt discount on notes payable	1,597,644		1,597,644
February 24 and June 19 combined Debt Issuance
Amortization of debt discount	67,095		98,698
VitaMed Promissory Note
Interest rate on promissory notes	4.00%		4.00%
Promisory notes, principal	500,000		500,000
Warrants Issued	613,718		613,718
Interest Expense	18,246		33,204
VitaMed Senior Secured Promissory Notes Interest Rate	6.00%		6.00%
VitaMed Senior Secured Promissory Notes Issued, balance of note converted	1,054,647		1,054,647
Notes converted to shares, number of shares	2,775,415		2,775,415
Conversion Price Per share	$ 0.38		$ 0.38
Notes conversion, value	100,000		100,000
Notes conversion Common Stock	266,822		266,822
Notes conversion Common Stock price	$ 0.38		$ 0.38
First United Line of Credit
Interest Expense	1,777		4,909
December 2011 Debt Issuance
Interest Expense	2,352		4,847
Promissory Note Individual
Interest rate on promissory notes	6.00%		6.00%
Promisory notes, principal	1,358,014		1,358,014
Promissory Note Individual \| February 24 Debt Issuance
Warrants Issued			4,500,000
Notes surrendered			1,347,128
Promissory Note Individual \| June 19 Debt Issuance
Promisory notes, principal	2,347,128		2,347,128
Promissory Note Entity
Interest rate on promissory notes	6.00%		6.00%
Promisory notes, principal	1,357,110		1,357,110
Promissory Note Entity \| February 24 Debt Issuance
Warrants Issued			4,500,000
Notes surrendered			1,344,719
Promissory Note Entity \| June 19 Debt Issuance
Promisory notes, principal	$ 2,344,719		$ 2,344,719

STOCKHOLDERS' EQUITY (Details) (USD $)	6 Months Ended
STOCKHOLDERS' EQUITY (Details) (USD $)	Jun. 30, 2012
Number of Shares Under Company Warrant
Balance Beginning	3,057,627
Granted	17,332,500
Exercised	(8,145,486)
Expired	0
Cancelled	0
Balance ending	12,244,641
Vested and exercisable	11,600,304
Warrant1Member
Balance Beginning	$ 0.36
Granted	$ 1.26
Balance ending	$ 1.62
Vested and exercisable	$ 1.69
Warrant2Member
Balance Beginning	7.9
Granted	4.8
Balance ending	5.3
Vested and exercisable	5.1
Aggregate Intrinstic Value
Balance Beginning	$ 3,483,691
Granted	$ 26,891,400
Balance ending	$ 14,644,646
Vested and exercisable	$ 13,065,984

STOCKHOLDERS' EQUITY (Details 2) (USD $)	3 Months Ended	6 Months Ended
STOCKHOLDERS' EQUITY (Details 2) (USD $)	Sep. 30, 2012	Jun. 30, 2012 Number of Shares Under Company Option	Jun. 30, 2012 Weighted Average Exercise Price	Jun. 30, 2012 Weighted Average Remaining Contractual Life in Years	Jun. 30, 2012 Aggregated Intrinstic Value
Balance Beginning		10,590,161
Granted		1,905,000
Exercised	30,685	(1,850,507)
Expired		0
Cancelled		(25,000)
Balance ending		10,619,654
Vested and exercisable		7,283,850
Balance Beginning			$ 0.16
Granted			$ 2.39
Balance ending			$ 0.58
Vested and exercisable			$ 0.13
Balance Beginning				7 years 5 months
Granted				9 years 9 months 18 days
Balance ending				7 years 5 months
Vested and exercisable				6 years 10 months 24 days
Balance Beginning					$ 14,067,649
Granted					$ 782,000
Balance ending					23,481,938
Vested and exercisable					$ 19,316,956

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	3 Months Ended			6 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	Sep. 30, 2012	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011	Aug. 09, 2012	Dec. 31, 2011
Common stock, shares authorized		250,000,000		250,000,000			250,000,000
Common stock, par value		$ 0.001		$ 0.001			$ 0.001
Common Stock Issued And Outstanding		95,750,212		95,750,212		95,800,807
Fair Value Modification Warrants Issued February 2012				$ 10,505,247
Debt discount on notes payable		1,597,644		1,597,644			0
Amortization of debt discount		1,055,984	3,590	1,109,276	3,590
Unamortized costs associated with Warrants		1,611,000		1,611,000
Shares authorized under LTIP plan		25,000,000		25,000,000
Shares authorized under SOP plan		10,000,000		10,000,000
Options exercised				1,630,022
Aggregate Purchase Price				166,000
Options to Employees				480,000
Options to employees exercise price				$ 2.40
Employee options vesting over four years		405,000		405,000
Employee options vesting over two years		60,000		60,000
Employee options vesting over twelve months		15,000		15,000
Noncash options exercised	21,338			245,485
Noncash options exercised aggregate purchase price				60,000
Noncash options exercised shares forfeited in lieu of cash	1,428			25,000
Noncash options exercised net options received	19,910			220,485
Weighted Average Issue Date Fair Value of Options Issued				$ 1.02
Share based compensation expense				529,129	98,236
Total Unrecognized Estimated Compensation Expense		1,683,000		1,683,000
Weighted Average Remaining Term		1.9		1.9
Warrants Issued in March 2012
Warrants issued for consulting services				31,000
Warrants issued for consulting services, Term				5
Warrants issued for consulting services, Volatility				44.81%
Warrants issued for consulting services, Risk Free Rate				1.04%
Warrants issued for consulting services, Dividend Yield				0.00%
Warrants issued for consulting services, Consulting Expense recognized				29,736
Warrants Issued in May 2012
Warrants issued for consulting services				1,300,000
Warrants issued for consulting services, Term				5
Warrants issued for consulting services, Volatility				44.71%
Warrants issued for consulting services, Risk Free Rate				0.74%
Warrants issued for consulting services, Dividend Yield				0.00%
FV of Warrants issued for consulting services				1,532,228
Warrants issued for consulting services, Prepaid Consulting Expense Short Term				306,446
Warrants issued for consulting services, Prepaid Consulting Expense Long Term				1,188,001
Warrants issued for consulting services, Consulting Expense recognized				37,781
Warrants Issued in June 2012
Warrants issued for consulting services				1,500
Warrants issued for consulting services, Term				5
Warrants issued for consulting services, Volatility				44.78%
Warrants issued for consulting services, Risk Free Rate				0.72%
Warrants issued for consulting services, Dividend Yield				0.00%
Warrants issued for consulting services, Consulting Expense recognized				1,656
February Directors Options Issuance
Options to purchase shares issued to Directors				600,000
Options exercise price for share		$ 2.20		$ 2.20
April Directors Options Issuance
Options to purchase shares issued to Directors				350,000
Options to purchase shares issued to Directors, per director				50,000
Additional Options to purchase shares issued to Directors				75,000
Additional Options to purchase shares issued to Directors, per director				25,000
Options exercise price for share		$ 2.55		$ 2.55
Options to purchase common stock issued to Dr. Bernick				150,000
June Directors Options Issuance
Options to purchase shares issued to Directors				250,000
Options exercise price for share		$ 2.80		$ 2.80
Director options vesting over a four-year period		7,500		7,500
Director options vesting over a two-year period		115,000		115,000
Director options vesting over a one-year period		2,500		2,500
Director options vesting monthly		75,000		75,000
Director options vesting immediately		50,000		50,000
Lower Range
Warrants exercise price		$ 0.24		$ 0.24
Option Exercise Price		$ 0.10		$ 0.10
Upper Range
Warrants exercise price		$ 3.00		$ 3.00
Option Exercise Price		$ 2.40		$ 2.40
February 24 Debt Issuance
Warrants Issued - Note Modification				5,685,300
Warrants Issued - new Funding				3,314,700
Exercise Price per share of warrants issued				$ 0.38
Fair Value Modification Warrants Issued February 2012				10,505,247
FV Warrants Issued - new Funding				6,124,873
FV Warrants - Assumptions in Black-Scholes Model				Term of 5 years; volatility of 44.5%; risk free rate of 0.89%; and a dividend yield of 0%
FV Warrants - treated as Debt Discount				859,647
Interest Expense				859,647
June 19 Debt Issuance
Warrants Issued - new Funding				7,000,000
Warrants Issued - new funding tranche 1				6,000,000
Warrants Issued - new funding tranche 1 exercise price				$ 2.00
Warrants Issued - new funding tranche 2				1,000,000
Warrants Issued - new funding tranche 2 exercise price				3.00
FV Warrants Issued - new Funding				9,424,982
FV Warrants - Assumptions in Black-Scholes Model				Term of 5 years; volatility of 44.64%; risk free rate of 0.75%; and a dividend yield of 0%
FV Warrants - treated as Debt Discount				1,649,890
Debt discount on notes payable		1,597,644		1,597,644
Amortization of debt discount		$ 52,246		$ 52,246

RELATED PARTIES (Details Narrative) (USD $)	6 Months Ended
RELATED PARTIES (Details Narrative) (USD $)	Jun. 30, 2012	Jun. 30, 2011	Dec. 31, 2011
Related Parties Details Narrative
Related Party Sales	$ 1,440	$ 11,505
Related Party Receivable	0		0
Related Party Purchases	96,250	0
Related Party Payables	$ 96,250		$ 0
Warrants Assigned	100,000

BUSINESS CONCENTRATIONS (Details Narrative)	3 Months Ended
BUSINESS CONCENTRATIONS (Details Narrative)	Jun. 30, 2012	Jun. 30, 2011
Business Concentrations Details Narrative
Purchase Concentration	87.00%	97.00%

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Commitments And Contingencies Details Narrative
Non-cancelable operating lease term	45
Monthly Base rent of leases	$ 5,443	$ 5,443
Share of monthly operating expenses	3,500	3,500
Rental Expense	56,918	56,908
Future minimum lease payments	$ 102,410

DEPOSITS HELD BY VENDORS (Details Narrative) (USD $)	3 Months Ended	6 Months Ended	12 Months Ended
DEPOSITS HELD BY VENDORS (Details Narrative) (USD $)	Jun. 30, 2012	Jun. 30, 2012	Dec. 31, 2011
Deposits Held By Vendors Details Narrative
Payments for Research and Development of New Products		$ 763,000	$ 245,000
Deposits charged to expense	579,000	873,000
Remaining balance of deposits	135,000	135,000
Estimated additional charge to be incurred in 2012	1,100,000	1,100,000
Downpayments for Inventory Purchases		309,000	55,000
Deposits applied to inventory purchases	61,000	127,000
Remaining balance of deposits	203,000	203,000
Downpayments for Inventory Purchase 2		63,000
Outstanding Accounts Payable to Vendor	$ 63,000	$ 63,000

SUBSEQUENT EVENTS (Details Narrative) (USD $)	3 Months Ended	6 Months Ended
SUBSEQUENT EVENTS (Details Narrative) (USD $)	Sep. 30, 2012	Jun. 30, 2012
Subsequent Events Details Narrative
Noncash options exercised	21,338	245,485
Options exercise price per share	$ 0.1873
Noncash options exercised shares forfeited in lieu of cash	1,428	25,000
Noncash options exercised net options received	19,910	220,485
Exercised	30,685
Options exercise price per share	$ 0.40735
Options Exercised, value	$ 12,459.69